MA31117B1 - Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes - Google Patents

Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Info

Publication number
MA31117B1
MA31117B1 MA32127A MA32127A MA31117B1 MA 31117 B1 MA31117 B1 MA 31117B1 MA 32127 A MA32127 A MA 32127A MA 32127 A MA32127 A MA 32127A MA 31117 B1 MA31117 B1 MA 31117B1
Authority
MA
Morocco
Prior art keywords
corticosteroids
receptor modulators
tricyclic compounds
compounds
salts
Prior art date
Application number
MA32127A
Other languages
Arabic (ar)
English (en)
Inventor
Rajesh Venkateswaran Devraj
Crescenzo Gary A De
Xiao Hu
Kevin Dewayne Jerome
Mark Gerard Obukowicz
Lisa Olson
Paul Vincent Rucker
Ronald Keith Webber
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA31117B1 publication Critical patent/MA31117B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)

Abstract

La présente invention concerne des composés de formule (i), ou leurs sels, qui sont des modulateurs du récepteur des glucocorticoïdes. Les composés et les sels de l'invention sont utiles dans le traitement d'affections médiées par l'activité des récepteurs des glucocorticoïdes.
MA32127A 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes MA31117B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
PCT/IB2008/000229 WO2008093227A1 (fr) 2007-02-02 2008-01-25 Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes

Publications (1)

Publication Number Publication Date
MA31117B1 true MA31117B1 (fr) 2010-01-04

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32128A MA31158B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32127A MA31117B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA32128A MA31158B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Country Status (42)

Country Link
US (7) US7547714B2 (fr)
EP (1) EP2114970B1 (fr)
JP (1) JP4599462B2 (fr)
KR (2) KR101107949B1 (fr)
CN (2) CN101616925B (fr)
AP (1) AP2455A (fr)
AR (2) AR065134A1 (fr)
AT (1) ATE518872T1 (fr)
AU (1) AU2008211613B2 (fr)
BR (1) BRPI0808634A2 (fr)
CA (1) CA2676670C (fr)
CL (2) CL2008000329A1 (fr)
CO (2) CO6220937A2 (fr)
CR (2) CR10949A (fr)
CU (2) CU20090133A7 (fr)
CY (2) CY1110962T1 (fr)
DK (1) DK2114970T3 (fr)
DO (1) DOP2009000190A (fr)
EA (1) EA016494B1 (fr)
EC (2) ECSP099552A (fr)
ES (2) ES2368286T3 (fr)
GE (2) GEP20125404B (fr)
GT (2) GT200900209A (fr)
HN (2) HN2008000178A (fr)
HR (1) HRP20110702T1 (fr)
IL (1) IL199972A (fr)
MA (2) MA31158B1 (fr)
MX (1) MX2009008284A (fr)
MY (3) MY153057A (fr)
NI (2) NI200900148A (fr)
NZ (1) NZ578638A (fr)
PE (2) PE20081736A1 (fr)
PL (1) PL2114970T3 (fr)
PT (2) PT2114970E (fr)
RS (2) RS51970B (fr)
SI (1) SI2114970T1 (fr)
SV (2) SV2009003346A (fr)
TN (1) TN2009000324A1 (fr)
TW (2) TWI347842B (fr)
UA (2) UA94639C2 (fr)
WO (1) WO2008093227A1 (fr)
ZA (2) ZA200906060B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (fr) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba et ses derives utilises pour le traitement de la douleur
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
BRPI0917212A2 (pt) 2008-07-28 2015-11-10 Pfizer compostos de fenantrenona, seus usos na preparação de composições, e composições compreendendo os referidos compostos
WO2010059894A1 (fr) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Formations oculaires de norkétotifène
US20100135908A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
WO2011141909A2 (fr) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Dérivés d'acide lipoïque et de nitroxide et leurs utilisations
BR112013004322A2 (pt) * 2010-08-27 2016-06-21 Corcept Therapeutics Inc moduladores de azadecalin fundidos com piridil-aminas
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
ES2824105T3 (es) 2014-05-16 2021-05-11 Olaplex Inc Formulaciones y métodos de tratamiento de queratina
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
WO2016149756A1 (fr) 2015-03-23 2016-09-29 The University Of Melbourne Traitement de maladies respiratoires
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
AU2019374731B2 (en) 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
PL207610B1 (pl) 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
WO2001005229A1 (fr) 1999-07-15 2001-01-25 The General Hospital Corporation Vecteur viral d'epstein-barr non defectueux
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
EP1201649B1 (fr) * 2000-10-28 2006-05-31 Pfizer Products Inc. Modulateurs du récepteur corticoide
ES2246292T3 (es) * 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
WO2002042995A1 (fr) * 2000-11-20 2002-05-30 Seagate Technology Llc Attache d'etiquette rfid a un disque dur
WO2003000226A2 (fr) 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
ATE411013T1 (de) 2001-08-31 2008-10-15 Corcept Therapeutics Inc Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
EP1432684B1 (fr) 2001-09-27 2009-03-25 Université de Liège Derives de sulfonamide pyridinique, procede de fabrication et d'utilisation
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1534299A4 (fr) 2002-07-02 2007-04-11 Corcept Therapeutics Inc Methodes de traitement de la psychose associee a une therapie aux interferon alpha
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
CA2504751C (fr) 2002-11-05 2013-02-05 Corcept Therapeutics, Inc. Procedes servant a traiter le reflux gastro-oesophagien pathologique
AU2004208842B2 (en) 2003-02-04 2009-05-28 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
WO2005047524A2 (fr) * 2003-11-10 2005-05-26 The Scripps Research Institute Compositions et procedes pour induire la differenciation cellulaire
EP1685110A1 (fr) * 2003-11-13 2006-08-02 Pfizer Products Inc. Derives d'octahydro-phenanthrene-hydrazide utiles en tant que modulateurs du recepteur des glucocorticoides
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja) 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
UZ4378C (en) * 2007-02-02 2011-07-29 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
DK2114970T3 (da) * 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer

Also Published As

Publication number Publication date
SI2114970T1 (sl) 2011-11-30
RS51970B (sr) 2012-02-29
MX2009008284A (es) 2009-08-12
US8445520B2 (en) 2013-05-21
CY1111758T1 (el) 2015-10-07
CN101616925B (zh) 2012-05-23
EA016494B1 (ru) 2012-05-30
CO6220937A2 (es) 2010-11-19
UA94639C2 (ru) 2011-05-25
WO2008093227A1 (fr) 2008-08-07
HRP20110702T1 (hr) 2011-10-31
US20080188443A1 (en) 2008-08-07
HN2008000178A (es) 2011-02-25
US8901310B2 (en) 2014-12-02
RS51646B (sr) 2011-10-31
TWI373466B (en) 2012-10-01
CN101616896A (zh) 2009-12-30
IL199972A (en) 2013-09-30
MY148780A (en) 2013-05-31
UA95332C2 (uk) 2011-07-25
CU20090132A7 (es) 2011-10-14
KR20090108115A (ko) 2009-10-14
CL2008000330A1 (es) 2008-08-08
AR065134A1 (es) 2009-05-20
NI200900149A (es) 2010-02-15
ATE518872T1 (de) 2011-08-15
NI200900148A (es) 2010-02-15
AP2009004942A0 (en) 2009-08-31
JP4599462B2 (ja) 2010-12-15
MY153057A (en) 2014-12-31
PE20090113A1 (es) 2009-02-13
CU23824A3 (es) 2011-10-31
US20120088802A9 (en) 2012-04-12
KR101114682B1 (ko) 2012-03-14
DK2114970T3 (da) 2011-09-19
US20140316139A1 (en) 2014-10-23
CA2676670A1 (fr) 2008-08-07
CR10949A (es) 2009-08-07
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
US7786097B2 (en) 2010-08-31
MY146087A (en) 2012-06-29
ES2368286T3 (es) 2011-11-16
PL2114970T3 (pl) 2011-11-30
CL2008000329A1 (es) 2008-08-08
CR10948A (es) 2009-08-07
DOP2009000190A (es) 2009-08-31
CN101616925A (zh) 2009-12-30
TW200846325A (en) 2008-12-01
JP2010517990A (ja) 2010-05-27
KR101107949B1 (ko) 2012-02-08
TWI347842B (en) 2011-09-01
SV2009003346A (es) 2010-04-13
US20100286214A1 (en) 2010-11-11
IL199972A0 (en) 2010-04-15
ES2353822T3 (es) 2011-03-07
ZA200906064B (en) 2010-05-26
US20090281148A1 (en) 2009-11-12
US20120095062A1 (en) 2012-04-19
US20140142316A1 (en) 2014-05-22
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
ZA200906060B (en) 2010-05-26
KR20090107080A (ko) 2009-10-12
MA31158B1 (fr) 2010-02-01
TW200838514A (en) 2008-10-01
US20080312294A1 (en) 2008-12-18
GT200900210A (es) 2010-04-05
AU2008211613A1 (en) 2008-08-07
ECSP099552A (es) 2009-08-28
PT2114970E (pt) 2011-09-22
SV2009003349A (es) 2010-04-13
TN2009000324A1 (fr) 2010-12-31
AR065135A1 (es) 2009-05-20
GEP20125404B (en) 2012-02-27
PT2114888E (pt) 2011-01-04
US7547714B2 (en) 2009-06-16
GEP20125426B (en) 2012-03-26
CU20090133A7 (es) 2011-10-31
NZ578638A (en) 2010-12-24
EP2114970B1 (fr) 2011-08-03
CO6190603A2 (es) 2010-08-19
CA2676670C (fr) 2012-03-13
EP2114970A1 (fr) 2009-11-11
AP2455A (en) 2012-08-31
CU23848B1 (es) 2012-10-15
HK1135108A1 (en) 2010-05-28
CN101616896B (zh) 2012-07-04
HN2008000179A (es) 2010-06-09
EA200970666A1 (ru) 2010-02-26
BRPI0808634A2 (pt) 2014-08-05
US7598231B2 (en) 2009-10-06
ECSP099553A (es) 2009-08-28
GT200900209A (es) 2010-07-22

Similar Documents

Publication Publication Date Title
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34474B1 (fr) Agonistes de gpr40
MA33155B1 (fr) Composes organiques et leurs utilisations
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
EP2004177A4 (fr) Composes de nitrofurane utilises dans le traitement du cancer et de l'angiogenese
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
DE602006019911D1 (de) Mglur1-antagonisten als therapeutische wirkstoffe
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
TNSN08275A1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines